Beximco Pharma

From Wikipedia, the free encyclopedia
  (Redirected from Beximco Pharmaceuticals Ltd)
Jump to: navigation, search

Beximco Pharmaceuticals Ltd (BPL) (DSE : BXPHARMA LSE: BXP), also known as Beximco Pharma, is a pharmaceutical company in Bangladesh.[1] It is part of the Beximco Group of Companies.

Beximco Pharmaceuticals Ltd. is a leading manufacturer of pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs) in Bangladesh. It is the flagship company of Beximco Group, the largest private sector industrial conglomerate in Bangladesh. Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory bodies of Australia, European Union, Gulf nations, Brazil, among others. The company is consistently building upon its portfolio and currently producing more than 500 products in different dosage forms covering broader therapeutic categories which include antibiotics, gastro-intestinals, respiratory, analgesics, cardiovascular, anti-diabetics, etc, among many others. With decades of contract manufacturing experience with global MNCs, skilled manpower and proven formulation capabilities, the company has been building a visible and growing presence across the continents offering high quality and affordable generics. Ensuring access to quality medicines is the powerful aspiration that motivates more than 2,700 employees of the organization, and each of them is guided by the same moral and social responsibilities the company values most. Beximco Pharma has the unique distinction as the only Bangladeshi company to get listed on the AIM of London Stock Exchange.

Beximco Pharma
Limited
Industry Pharmaceutical
Founded 1980
Headquarters Tongi, Dhaka, Bangladesh
Key people
Nazmul Hassan (MD)
Website [1]

Corporate history[edit]

Beximco Pharma was founded in 1976 and started operations in 1980, manufacturing products under the licenses of Bayer AG of Germany and Upjohn Inc. of USA. It has now grown to become a leading pharmaceutical company in Bangladesh, and it supplies more than 10% of country's total medicinal needs. Today Beximco Pharma manufactures and markets its own branded generics for several diseases including AIDS, cancer, asthma, hypertension, and diabetes for both national and international markets.

Manufacturing Capabilities[edit]

Situated near Dhaka, Bangladesh, the capital city of Bangladesh, Beximco Pharmaceuticals' manufacturing site extends over an area of 23-acre (93,000 m2). This main site houses manufacturing facilities for producing various drugs in different strengths and delivery systems such as capsules, tablets, intravenous fluids, metered dose inhalers, sterile ophthalmic drops, prefilled syringes, dry powder inhalers, injectables and nebulizer solutions etc. The site has its own utility infrastructure to ensure adequate generation and distribution of electricity with an installed capacity of 10 MW, in addition to water purifying and liquid nitrogen generation facilities. The bulk drug unit for producing paracetamol is also located within this site while the penicillin API and formulation units are situated at Kaliakoir, a few kilometers from the main site.

The facilities consist of a number of purpose-built plants, including a new Oral Solid Dosage (OSD) plant. The site includes manufacturing facilities as well as a research laboratory and a number of warehouses. The plant and machinery of the facilities were designed, produced and installed by partners from Germany, Switzerland, Sweden, Italy and the United Kingdom, amongst others.

Oral Solid Dosage[edit]

The state-of-the-art Oral Solid Dosage unit is designed as per US FDA standards. The facility incorporates contemporary technological advancements with automated material handling systems and multilevel designs to enable gravity feed between various processing stages. This facility houses a total of five lines with an annual capacity to produce 5 billion tablets on a single shift basis. Beximco Pharma’s modern OSD facility is already accredited by the regulatory authorities of EU, Australia and the Gulf member states, and the Company is highly focused on entering the regulated markets of US, EU and Australia.

Metered Dose Inhaler[edit]

Beximco Pharma was among the first few companies in the world who made the transition away from CFC-based inhalers to the ozone benign HFA based formulations, in compliance with the Montreal Protocol. The Company proactively developed ozone benign HFA based MDIs which require very high level of expertise and sophisticated technology. Beximco Pharma is currently the largest producer of MDIs in Bangladesh, and it produces a popular inhaler brand for a global MNC under a contract manufacturing agreement. The MDI units have been designed with the technical collaboration from Pamasol, Switzerland; which now have an annual production capacity of 20 million canisters.

Ophthalmic[edit]

Beximco Pharma’s ophthalmic facility was launched in 2009. Today this facility has been accredited by the regulatory authorities of EU and Australia and the Company has differentiated itself by maintaining global quality standards. There is increasing response from European clients where the demand for generic ophthalmic products is rising due to patent expiration of a number of key products. Currently a good number of ophthalmic products are being manufactured which include products like Xalaprost (Latanoprost), Xalanol (Latanoprost+Timolol), Odycin (Moxifloxacin), Olopan (Olopatadine),etc.

Intravenous Fluid[edit]

Beximco Pharma’s Intravenous (IV) fluid unit is ISO 9001: 2010 certified and was designed in collaboration with Pharmaplan, a sister concern of Fresenius AG of Germany. Absolute sterile manufacturing conditions are rigorously maintained through a series of fully automated manufacturing procedures including the robotics. The facility utilizes FFS (Form-Fill-Seal) BottlePack® aseptic system of Pharmaplan Germany. Plastic bottles are blow molded, filled with the solution and sealed under sterile conditions, in a single working cycle where there is no environmental exposure or human contact during manufacturing. The whole process is performed in a Class 100 clean room which ensures the highest standards of quality and purity. The facility produces a broad assortment of large volume parenterals (LVPs). As a line extension of this IV unit, the company has installed amino acid line to produce a range of parenteral nutrition products such as Nutrimin D (7% Composite Amino Acid IV Infusion with 10% Glucose and Electrolytes), Dexaqua (Dextrose 5%), Dexoride 500 (Sodium Chloride 0.9% and Dextrose 5%) etc.

Liquid and Semisolid[edit]

Beximco Pharma has a broad range of liquid formulations like syrups etc. and semisolid dosage forms including creams and ointments. At present the capacity of liquid dosage facility is 37 million units per annum and the Company has taken up expansion program along with further upgradation of the existing unit to meet the growing demand. The Company currently has the capacity to produce 6 million units of creams and ointments and 10 million units of suppositories.

Prefilled Syringe[edit]

Prefilled syringes (PFS) provide both convenience and accuracy to self-administered drugs. With their ease of use and improved safety features, PFS has become one of most widely used drug delivery systems today. Beximco Pharma launched PFS range with enoxaparin sodium, a low molecular weight heparin, which is widely used in cardiac emergency. The Company plans to add a few more high value products to its PFS portfolio shortly. The high precision PFS line employs sophisticated technology and the entire filling operation is done under laminar flow in a Class 100 environment to provide absolute sterile conditions.

Dry Powder Inhaler

Dry powder inhaler (DPI) is a device that delivers medication to the lungs in the form of a dry powder. DPIs do not require the timing and coordination that are necessary with metered-dose inhaler and they do not contain any propellants. Beximco Pharma offers dry powder inhaler in innovative patient-friendly packaging. Instead of bottle pack, Beximco Pharmaprovide alu-alu blister pack which protects medicine from moisture. HPMC capsule shell ensures maximum protection against moisture. And Beximco Pharma’sunique and simple Bexihaler® device, imported from Europe, and consisting of 8 pins, ensures optimum dose delivery. Currently the facility has the capacity to produce 36 million units of DPI every year.

Lyophilized Injectable[edit]

Lyophilization is a complex and facility-intensive operation where Beximco has demonstrated its skill through quick and successful adoption of this relatively newer technology. The company within a short span of time emerges as an important player in this area with its range of PPIs and other formulations.

GMP Accreditations[edit]

At present Beximco Pharma has the highest number of international accreditations in the country which include: AGES, Austria (European Union) Therapeutic Goods Administration (TGA), Australia ANVISA, Brazil INVIMA, Colombia* MCC, South Africa*


Global Footprint[edit]

Beximco Pharma is the only pharma company in the country which has won the National Export Trophy (Gold) a record four times. This is the highest recognition for the companies in the export sector for significant contribution to Bangladesh's economic growth.

On August, 2007, Beximco exported its medicines to the Philippines, the 5th country of the 10-member Association of South East Asian Nations (ASEAN) to import Beximco's drugs. Beximco Managing Director Nazmul Hassan said that exports to the Philippines include metered dose inhalers, and nasal sprays, and other medications. The Philippine pharmaceutical market ($1.3 billion in 2007), is highly dependent on imported medicines.[2]

At the moment, Beximco Pharma have the highest number of international accreditations in the country and Beximco Pharma aim to leverage their resources as they venture into new territories. Beximco Pharma have so far expanded their global footprint to 47 countries across the continents and their strategy is to capitalize further on the generic drug opportunities. In addition to strengthening Beximco Pharma position in current export markets, they are targeting export opportunities in new overseas markets, particularly in the regulated and emerging markets.

Beximco Pharma products have been well received in the overseas markets and their global customers include reputed institutions such as the Raffles Hospital, Heathway and K K Women's & Children's Hospital in Singapore, MEDS and Kenyatta National Hospital, Kenya, among others. Beximco Pharma is also an enlisted supplier for UNICEF (United Nations International Children's Emergency Fund), Save the Children, WHO (World Health Organization) and ADF (Asthma Drug Facility)

References[edit]

External links[edit]